Free Trial
NYSE:ALVO

Alvotech (ALVO) Stock Price, News & Analysis

$14.00
+0.06 (+0.43%)
(As of 04:00 PM ET)
Today's Range
$13.97
$14.30
50-Day Range
$11.40
$15.39
52-Week Range
$6.70
$18.00
Volume
405,150 shs
Average Volume
267,993 shs
Market Capitalization
$437.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.67
ALVO stock logo

About Alvotech Stock (NYSE:ALVO)

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

ALVO Stock Price History

ALVO Stock News Headlines

Alvotech and Dr Reddy’s partner to commercialise AVT03
ALVO Stock Earnings: Alvotech Misses EPS for Q1 2024
Alvotech (ALVO) Scheduled to Post Quarterly Earnings on Tuesday
Alvotech (ALVO)
Alvotech expands US reach with biosimilar to Humira
See More Headlines
Receive ALVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alvotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/21/2024
Today
5/22/2024
Next Earnings (Estimated)
5/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Fax
N/A
Employees
1,026
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.67
High Stock Price Target
$20.00
Low Stock Price Target
$8.00
Potential Upside/Downside
-9.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-551,730,000.00
Net Margins
-967.97%
Pretax Margin
-712.04%

Debt

Sales & Book Value

Annual Sales
$93.38 million

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
-0.02
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Robert Wessman (Age 54)
    CEO, Founder & Executive Chairman
    Comp: $1.52M
  • Mr. Faysal Kalmoua (Age 48)
    COO & Director
  • Mr. Joel Morales (Age 46)
    Chief Financial Officer
  • Mr. Giedrius Zunda
    Chief Technical Officer
  • Mr. Joseph E. McClellan (Age 50)
    Chief Scientific Officer
  • Ms. Tanya Zharov (Age 57)
    General Counsel
  • Ms. Jenny Sif Steingrimsdottir
    Vice President of People & Culture
  • Mr. Anil Okay (Age 38)
    Chief Commercial Officer
  • Mr. Ming Li (Age 47)
    Chief Strategy Officer
  • Ms. Christina Siniscalchi
    Chief Quality Officer

ALVO Stock Analysis - Frequently Asked Questions

Should I buy or sell Alvotech stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alvotech in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALVO shares.
View ALVO analyst ratings
or view top-rated stocks.

What is Alvotech's stock price target for 2024?

2 brokers have issued 1-year price targets for Alvotech's stock. Their ALVO share price targets range from $8.00 to $20.00. On average, they anticipate the company's stock price to reach $12.67 in the next year. This suggests that the stock has a possible downside of 9.5%.
View analysts price targets for ALVO
or view top-rated stocks among Wall Street analysts.

How have ALVO shares performed in 2024?

Alvotech's stock was trading at $11.48 at the start of the year. Since then, ALVO shares have increased by 22.0% and is now trading at $14.00.
View the best growth stocks for 2024 here
.

When is Alvotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, September 4th 2024.
View our ALVO earnings forecast
.

How were Alvotech's earnings last quarter?

Alvotech (NYSE:ALVO) posted its quarterly earnings results on Tuesday, May, 21st. The company reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.81. The firm had revenue of $36.89 million for the quarter. During the same period in the prior year, the business posted ($1.24) earnings per share.

What guidance has Alvotech issued on next quarter's earnings?

Alvotech updated its FY 2024 earnings guidance on Tuesday, May, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $400.0 million-$500.0 million, compared to the consensus revenue estimate of $318.6 million.

Who are Alvotech's major shareholders?

Alvotech's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.00%), Bracebridge Capital LLC (0.00%) and Littlejohn & Co. LLC (3.90%).

How do I buy shares of Alvotech?

Shares of ALVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ALVO) was last updated on 5/22/2024 by MarketBeat.com Staff

From Our Partners